Published in J Clin Invest on February 15, 2016
Epigenetic therapies by targeting aberrant histone methylome in AML: molecular mechanisms, current preclinical and clinical development. Oncogene (2016) 0.77
Lysine-specific histone demethylases in normal and malignant hematopoiesis. Exp Hematol (2016) 0.76
Functional screen of MSI2 interactors identifies an essential role for SYNCRIP in myeloid leukemia stem cells. Nat Genet (2017) 0.75
JMJD1C Exhibits Multiple Functions in Epigenetic Regulation during Spermatogenesis. PLoS One (2016) 0.75
JMJD1C Ensures Mouse Embryonic Stem Cell Self-Renewal and Somatic Cell Reprogramming through Controlling MicroRNA Expression. Stem Cell Reports (2017) 0.75
Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A (2005) 167.46
Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res (1983) 124.30
Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science (1999) 83.27
Differential expression analysis for sequence count data. Genome Biol (2010) 64.56
PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet (2003) 53.59
Stem cells, cancer, and cancer stem cells. Nature (2001) 50.27
STAR: ultrafast universal RNA-seq aligner. Bioinformatics (2012) 25.21
Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Nature (2003) 14.35
MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet (2001) 13.79
Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature (2003) 12.06
Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature (2006) 11.90
A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer (2011) 11.33
A conditional knockout resource for the genome-wide study of mouse gene function. Nature (2011) 9.93
MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer (2007) 8.17
MLL targets SET domain methyltransferase activity to Hox gene promoters. Mol Cell (2002) 8.17
Cancer epigenetics: from mechanism to therapy. Cell (2012) 7.74
Highly parallel identification of essential genes in cancer cells. Proc Natl Acad Sci U S A (2008) 7.45
Deconstructing stem cell self-renewal: genetic insights into cell-cycle regulation. Nat Rev Genet (2008) 7.30
ALL-1 is a histone methyltransferase that assembles a supercomplex of proteins involved in transcriptional regulation. Mol Cell (2002) 6.72
Altered Hox expression and segmental identity in Mll-mutant mice. Nature (1995) 6.60
Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia. Cancer Cell (2006) 6.34
Hoxa9 transforms primary bone marrow cells through specific collaboration with Meis1a but not Pbx1b. EMBO J (1998) 5.21
Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia. Nature (2009) 4.99
The role of mutations in epigenetic regulators in myeloid malignancies. Nat Rev Cancer (2012) 4.97
MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell (2011) 4.56
The Wnt/beta-catenin pathway is required for the development of leukemia stem cells in AML. Science (2010) 4.37
Meis1 is an essential and rate-limiting regulator of MLL leukemia stem cell potential. Genes Dev (2007) 4.07
Count-based differential expression analysis of RNA sequencing data using R and Bioconductor. Nat Protoc (2013) 4.00
Transformation of myeloid progenitors by MLL oncoproteins is dependent on Hoxa7 and Hoxa9. Genes Dev (2003) 4.00
Gene expression profiling of pediatric acute myelogenous leukemia. Blood (2004) 3.77
Hoxa9 and Meis1 are key targets for MLL-ENL-mediated cellular immortalization. Mol Cell Biol (2004) 3.62
Two classes of proteins dependent on either the presence or absence of thyroid hormone for interaction with the thyroid hormone receptor. Mol Endocrinol (1995) 3.59
Hox genes in hematopoiesis and leukemogenesis. Oncogene (2007) 3.55
HOXA9 is required for survival in human MLL-rearranged acute leukemias. Blood (2008) 3.12
Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation. Cancer Cell (2008) 3.01
Unique and independent roles for MLL in adult hematopoietic stem cells and progenitors. Cell Stem Cell (2007) 2.82
Cell cycle regulation in hematopoietic stem cells. J Cell Biol (2011) 2.48
An integrated approach to dissecting oncogene addiction implicates a Myb-coordinated self-renewal program as essential for leukemia maintenance. Genes Dev (2011) 2.38
A previously unidentified alternatively spliced isoform of t(8;21) transcript promotes leukemogenesis. Nat Med (2006) 2.36
An Mll-dependent Hox program drives hematopoietic progenitor expansion. Curr Biol (2004) 2.10
Growth disturbance in fetal liver hematopoiesis of Mll-mutant mice. Blood (1998) 2.06
Loss of expression of the Hoxa-9 homeobox gene impairs the proliferation and repopulating ability of hematopoietic stem cells. Blood (2005) 2.06
Simultaneous loss of beta- and gamma-catenin does not perturb hematopoiesis or lymphopoiesis. Blood (2007) 2.06
CBX8, a polycomb group protein, is essential for MLL-AF9-induced leukemogenesis. Cancer Cell (2011) 2.01
Requirement for Dot1l in murine postnatal hematopoiesis and leukemogenesis by MLL translocation. Blood (2011) 1.99
Hoxa9 influences the phenotype but not the incidence of Mll-AF9 fusion gene leukemia. Blood (2003) 1.93
Leukemic transformation of hematopoietic progenitors by MLL-GAS7 in the absence of Hoxa7 or Hoxa9. Blood (2003) 1.84
VavCre transgenic mice: a tool for mutagenesis in hematopoietic and endothelial lineages. Genesis (2002) 1.73
Identification and characterization of Hoxa9 binding sites in hematopoietic cells. Blood (2011) 1.63
Hedgehog signaling is dispensable for adult murine hematopoietic stem cell function and hematopoiesis. Cell Stem Cell (2009) 1.61
Polycomb repressive complex 2 regulates normal hematopoietic stem cell function in a developmental-stage-specific manner. Cell Stem Cell (2013) 1.56
Megakaryocytes maintain homeostatic quiescence and promote post-injury regeneration of hematopoietic stem cells. Nat Med (2014) 1.52
Polycomb repressive complex 2 is required for MLL-AF9 leukemia. Proc Natl Acad Sci U S A (2012) 1.52
In Vivo RNAi screening identifies a leukemia-specific dependence on integrin beta 3 signaling. Cancer Cell (2013) 1.42
Abrogation of MLL-AF10 and CALM-AF10-mediated transformation through genetic inactivation or pharmacological inhibition of the H3K79 methyltransferase Dot1l. Leukemia (2012) 1.36
HOX expression patterns identify a common signature for favorable AML. Leukemia (2008) 1.24
The methyltransferase G9a regulates HoxA9-dependent transcription in AML. Genes Dev (2014) 1.23
Continuous MLL-ENL expression is necessary to establish a "Hox Code" and maintain immortalization of hematopoietic progenitor cells. Cancer Res (2005) 1.18
Novel somatic and germline mutations in intracranial germ cell tumours. Nature (2014) 1.14
A novel variant of the putative demethylase gene, s-JMJD1C, is a coactivator of the AR. Arch Biochem Biophys (2007) 1.11
iCanPlot: visual exploration of high-throughput omics data using interactive Canvas plotting. PLoS One (2012) 1.10
Recent progress toward epigenetic therapies: the example of mixed lineage leukemia. Blood (2013) 1.08
JMJD1C demethylates MDC1 to regulate the RNF8 and BRCA1-mediated chromatin response to DNA breaks. Nat Struct Mol Biol (2013) 1.05
Regulation of mouse steroidogenesis by WHISTLE and JMJD1C through histone methylation balance. Nucleic Acids Res (2010) 1.02
Protein complex interactor analysis and differential activity of KDM3 subfamily members towards H3K9 methylation. PLoS One (2013) 0.99
shRNA screening identifies JMJD1C as being required for leukemia maintenance. Blood (2014) 0.95
Essential role of DOT1L in maintaining normal adult hematopoiesis. Cell Res (2011) 0.93
Epigenetic regulation of miR-302 by JMJD1C inhibits neural differentiation of human embryonic stem cells. J Biol Chem (2013) 0.88
JMJD1C, a JmjC domain-containing protein, is required for long-term maintenance of male germ cells in mice. Biol Reprod (2013) 0.85
Transformation from committed progenitor to leukemia stem cells. Ann N Y Acad Sci (2009) 0.83
Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A (2005) 167.46
MicroRNA expression profiles classify human cancers. Nature (2005) 69.12
The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88
The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science (2006) 25.99
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell (2005) 17.41
High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68
FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress. Cell (2007) 12.33
Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature (2006) 11.90
Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell (2006) 10.29
Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med (2011) 9.90
WDR5 associates with histone H3 methylated at K4 and is essential for H3 K4 methylation and vertebrate development. Cell (2005) 8.86
MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer (2007) 8.17
MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med (2006) 7.95
Densely interconnected transcriptional circuits control cell states in human hematopoiesis. Cell (2011) 7.03
Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med (2014) 6.12
Physical association and coordinate function of the H3 K4 methyltransferase MLL1 and the H4 K16 acetyltransferase MOF. Cell (2005) 6.12
Regulation of MLL1 H3K4 methyltransferase activity by its core components. Nat Struct Mol Biol (2006) 6.03
Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood (2009) 5.72
HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer. Nature (2009) 5.48
Human PAD4 regulates histone arginine methylation levels via demethylimination. Science (2004) 5.46
Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. Nature (2010) 5.43
Chromatin structure analyses identify miRNA promoters. Genes Dev (2008) 5.40
Ordered cooperative functions of PRMT1, p300, and CARM1 in transcriptional activation by p53. Cell (2004) 5.30
Stem cell gene expression programs influence clinical outcome in human leukemia. Nat Med (2011) 5.24
H3K79 methylation profiles define murine and human MLL-AF4 leukemias. Cancer Cell (2008) 5.23
Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell (2011) 4.90
(R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science (2013) 4.88
MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell (2011) 4.56
The metazoan Mediator co-activator complex as an integrative hub for transcriptional regulation. Nat Rev Genet (2010) 4.46
Ribosomopathies: human disorders of ribosome dysfunction. Blood (2010) 4.43
Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science (2013) 4.39
The Wnt/beta-catenin pathway is required for the development of leukemia stem cells in AML. Science (2010) 4.37
Dynamic regulation of pol II transcription by the mammalian Mediator complex. Trends Biochem Sci (2005) 4.37
Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. J Exp Med (2008) 4.25
Chromatin-modifying enzymes as modulators of reprogramming. Nature (2012) 4.22
S phase activation of the histone H2B promoter by OCA-S, a coactivator complex that contains GAPDH as a key component. Cell (2003) 4.03
The N-CoR-HDAC3 nuclear receptor corepressor complex inhibits the JNK pathway through the integral subunit GPS2. Mol Cell (2002) 3.99
Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell (2006) 3.93
MicroRNA-mediated control of cell fate in megakaryocyte-erythrocyte progenitors. Dev Cell (2008) 3.84
RAD6-Mediated transcription-coupled H2B ubiquitylation directly stimulates H3K4 methylation in human cells. Cell (2009) 3.82
Changes in the pattern of DNA methylation associate with twin discordance in systemic lupus erythematosus. Genome Res (2009) 3.81
Regulation of the p300 HAT domain via a novel activation loop. Nat Struct Mol Biol (2004) 3.70
Activation of beta-catenin signaling in articular chondrocytes leads to osteoarthritis-like phenotype in adult beta-catenin conditional activation mice. J Bone Miner Res (2009) 3.61
Chemically ubiquitylated histone H2B stimulates hDot1L-mediated intranucleosomal methylation. Nature (2008) 3.55
Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells. Cancer Cell (2010) 3.46
Transcription coactivator TRAP220 is required for PPAR gamma 2-stimulated adipogenesis. Nature (2002) 3.42
Menin and MLL cooperatively regulate expression of cyclin-dependent kinase inhibitors. Proc Natl Acad Sci U S A (2005) 3.37
Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. Cancer Cell (2007) 3.23
HOXA9 is required for survival in human MLL-rearranged acute leukemias. Blood (2008) 3.12
Retracted GlcNAcylation of a histone methyltransferase in retinoic-acid-induced granulopoiesis. Nature (2009) 3.10
A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms. Nat Genet (2009) 3.10
Acetylation of p53 augments its site-specific DNA binding both in vitro and in vivo. Proc Natl Acad Sci U S A (2004) 3.06
Long noncoding RNA high expression in hepatocellular carcinoma facilitates tumor growth through enhancer of zeste homolog 2 in humans. Hepatology (2011) 3.05
mAM facilitates conversion by ESET of dimethyl to trimethyl lysine 9 of histone H3 to cause transcriptional repression. Mol Cell (2003) 2.97
Base-pair resolution DNA methylation sequencing reveals profoundly divergent epigenetic landscapes in acute myeloid leukemia. PLoS Genet (2012) 2.94
Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. J Clin Oncol (2012) 2.92
Prognostic value of a microRNA signature in nasopharyngeal carcinoma: a microRNA expression analysis. Lancet Oncol (2012) 2.91
Genetic and pharmacologic inhibition of β-catenin targets imatinib-resistant leukemia stem cells in CML. Cell Stem Cell (2012) 2.89
MLL associates specifically with a subset of transcriptionally active target genes. Proc Natl Acad Sci U S A (2005) 2.87
Haploinsufficiency for ribosomal protein genes causes selective activation of p53 in human erythroid progenitor cells. Blood (2010) 2.84
The human homolog of yeast BRE1 functions as a transcriptional coactivator through direct activator interactions. Mol Cell (2005) 2.79
AKT/FOXO signaling enforces reversible differentiation blockade in myeloid leukemias. Cell (2011) 2.77
Activating signal cointegrator 2 belongs to a novel steady-state complex that contains a subset of trithorax group proteins. Mol Cell Biol (2003) 2.70
Unraveling the molecular pathophysiology of myelodysplastic syndromes. J Clin Oncol (2011) 2.69
30 nm chromatin fibre decompaction requires both H4-K16 acetylation and linker histone eviction. J Mol Biol (2008) 2.62
Metagene projection for cross-platform, cross-species characterization of global transcriptional states. Proc Natl Acad Sci U S A (2007) 2.60
The impact of operative time on complications after plastic surgery: a multivariate regression analysis of 1753 cases. Aesthet Surg J (2014) 2.57
Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemia. Nat Med (2010) 2.50
ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. Cancer Cell (2012) 2.42
Failure to prolyl hydroxylate hypoxia-inducible factor alpha phenocopies VHL inactivation in vivo. EMBO J (2006) 2.41
Correction of sickle cell disease in adult mice by interference with fetal hemoglobin silencing. Science (2011) 2.36
Androgen receptor is a new potential therapeutic target for the treatment of hepatocellular carcinoma. Gastroenterology (2008) 2.36
Gene expression signatures in MLL-rearranged T-lineage and B-precursor acute leukemias: dominance of HOX dysregulation. Blood (2003) 2.35
Coordination of p300-mediated chromatin remodeling and TRAP/mediator function through coactivator PGC-1alpha. Mol Cell (2003) 2.31
Role for Dpy-30 in ES cell-fate specification by regulation of H3K4 methylation within bivalent domains. Cell (2011) 2.30
p300 and PCAF act cooperatively to mediate transcriptional activation from chromatin templates by notch intracellular domains in vitro. Mol Cell Biol (2002) 2.29
Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. Nature (2012) 2.28
A unified nomenclature for protein subunits of mediator complexes linking transcriptional regulators to RNA polymerase II. Mol Cell (2004) 2.27
Multiple interactions recruit MLL1 and MLL1 fusion proteins to the HOXA9 locus in leukemogenesis. Mol Cell (2010) 2.25
The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors. Blood (2011) 2.23
Blue photoluminescence from chemically derived graphene oxide. Adv Mater (2010) 2.22
The human PAF1 complex acts in chromatin transcription elongation both independently and cooperatively with SII/TFIIS. Cell (2010) 2.20
Suppression of the antiviral response by an influenza histone mimic. Nature (2012) 2.18
Coactivator as a target gene specificity determinant for histone H3 lysine 4 methyltransferases. Proc Natl Acad Sci U S A (2006) 2.16
Small-molecule inhibitors of HIF-2a translation link its 5'UTR iron-responsive element to oxygen sensing. Mol Cell (2008) 2.15
GlcNAcylation of histone H2B facilitates its monoubiquitination. Nature (2011) 2.14
Overexpression of cyclin D1 promotes tumor cell growth and confers resistance to cisplatin-mediated apoptosis in an elastase-myc transgene-expressing pancreatic tumor cell line. Clin Cancer Res (2005) 2.13
BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia. Blood (2007) 2.12
Role of SWI/SNF in acute leukemia maintenance and enhancer-mediated Myc regulation. Genes Dev (2013) 2.07
mTOR complex 1 plays critical roles in hematopoiesis and Pten-loss-evoked leukemogenesis. Cell Stem Cell (2012) 2.06
A tumor suppressive coactivator complex of p53 containing ASC-2 and histone H3-lysine-4 methyltransferase MLL3 or its paralogue MLL4. Proc Natl Acad Sci U S A (2009) 2.06